Hebei Medical University Pharmaceutical Factory

Hebei Medical University Pharmaceutical Factory is a pharmaceutical manufacturing enterprise owned by Hebei Medical University, located in Shijiazhuang, China. The company specializes in the production of chemical APIs and finished dosage forms, with a strong historical focus on neurology, infectious diseases, and ophthalmology. It is notably recognized for its role in the early development of Butylphthalide (NBP), a major stroke treatment later commercialized by CSPC. Currently, the factory produces a range of generic medications including Edaravone for stroke, Adefovir and Emtricitabine for hepatitis B, and various ophthalmic and cardiovascular treatments. As a university-affiliated entity, it integrates academic research with industrial production, maintaining GMP-certified facilities to supply both domestic and international markets.